UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): December 7, 2019
Stoke Therapeutics, Inc.
(Exact Name of Registrant as Specified in its Charter)
Delaware | 001-38938 | 47-114582 | ||
(State or other jurisdiction of incorporation or organization) | (Commission File Number) | (I.R.S. Employer Identification No.) | ||
45 Wiggins Ave Bedford, Massachusetts | 01730 | |||
(Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including area code:(781) 430-8200
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
☐ | Soliciting material pursuant to Rule14a-12 under the Exchange Act (17 CFR240.14a-12) |
☐ | Pre-commencement communications pursuant to Rule14d-2(b) under the Exchange Act (17 CFR240.14d-2(b)) |
☐ | Pre-commencement communications pursuant to Rule13e-4(c) under the Exchange Act (17 CFR240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
Common Stock, $0.0001 par value per share | STOK | Nasdaq Global Select Market |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule12b-2 of the Securities Exchange Act of 1934(§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 7.01 Regulation FD.
On December 7, 2019, Stoke Therapeutics, Inc. issued a press release announcing preclinical data from studies ofSTK-001 that showed significant improvements in survival and reductions in seizure frequency in a Dravet syndrome mouse model. A copy of the press release is attached as Exhibit 99.1 to this report.
On December 8, 2019, Stoke Therapeutics, Inc. issued an additional press release announcing dose-dependent target engagement and increased protein expression in the brain ofnon-human primates after a single intrathecal injection. A copy of the press release is attached as Exhibit 99.2 to this report.
The information furnished with this report, including Exhibit 99.1 and Exhibit 99.2, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (“Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit Number | Description | |
99.1 | Press release issued by Stoke Therapeutics, Inc., dated December 7, 2019. | |
99.2 | Press release issued by Stoke Therapeutics, Inc., dated December 8, 2019. |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
STOKE THERAPEUTICS, INC. | ||||
Date: December 9, 2019 | By: | /s/ Stephen J. Tulipano | ||
Stephen J. Tulipano | ||||
Chief Financial Officer |